At December 31, 2023, ProQR held cash and cash equivalents of EUR 118.9 million, compared to EUR 94.8 million at December 31, 2022. Net cash generated by operating activities during the full year ended December 31, 2023 was EUR 21.5 million, compared to EUR 68.5 million net cash used in operating activities for the same period in 2022. The Company experienced a net positive cash flow from operating activities in 2023 primarily due to the receipt of the Lilly up-front payment of $60 million in February 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRQR:
- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Therapeutics BV (PRQR) Q4 Earnings Cheat Sheet
- ProQR Therapeutics announces Japanese Axiomer patent upheld
- Biotech Alert: Searches spiking for these stocks today
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
